ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 63.65% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2013-03-31 was 67.00%, a 23.86% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2012-12-31 was 70.00%, a 23.08% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2012-03-31 was 88.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for the quarter ending 2011-12-31 was 91.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2022 was 78.00%, a 2.63% increase from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2021 was 76.00%, a 5.56% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2020 was 72.00%, a 5.26% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2019 was 76.00%, a 15.56% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 63.65% S-1 · filed 2026-09-11 | ||||
| 2023-12-31 | 79.10% S-1 · filed 2026-09-11 | ||||
| 2022-12-31 | 78.00% 10-K · filed 2023-03-31 | ||||
| 2021-12-31 | 76.00% 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | 72.00% 10-K · filed 2022-03-30 | ||||
| 2019-12-31 | 76.00% 10-K · filed 2022-03-30 | ||||
| 2018-12-31 | 90.00% 10-K · filed 2021-03-12 | 90.30% 10-K · filed 2019-03-14 | |||
| 2017-12-31 | 87.00% 10-K · filed 2020-03-06 | 87.17% 10-K · filed 2018-03-16 | |||
| 2016-12-31 | 64.46% 10-K · filed 2019-03-14 | ||||
| 2016-06-30 | 69.00% 10-K · filed 2017-10-13 | ||||
| 2015-12-31 | 73.70% 10-K · filed 2018-03-16 | ||||
| 2015-06-30 | 95.00% 10-K · filed 2017-10-13 | ||||
| 2014-06-30 | 85.00% 10-K · filed 2016-10-13 | ||||
| 2013-06-30 | 67.00% 10-K · filed 2015-10-09 | ||||
| 2013-03-31 | 67.00% 10-Q · filed 2013-05-15 | 67.00% 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | 70.00% 10-Q · filed 2013-02-14 | 70.00% 10-Q · filed 2013-02-14 | |||
| 2012-06-30 | 78.00% 10-K · filed 2014-09-29 | ||||
| 2012-03-31 | 88.00% 10-Q · filed 2013-05-15 | 88.00% 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | 91.00% 10-Q · filed 2013-02-14 | 91.00% 10-Q · filed 2013-02-14 | |||
| 2011-09-30 | 102.00% 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | 103.00% 10-K · filed 2013-09-11 | ||||
| 2010-06-30 | 100.00% 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |